September 2010 DAIT Council-Approved Concepts
Concepts represent early planning stages for program announcements, request for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to the Opportunities and Announcements portal.
NB: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Allergen Epitope Validation Resource
For the published request for applications, see the April 7, 2011, Guide announcement, Allergen Epitope Research and Validation Centers.
Cooperative Study Group for Autoimmune Disease Prevention
For the published request for applications, see the June 17, 2011, Guide announcement.
Stem Cell Transplantation for the Treatment of Scleroderma
Request for Proposals - JOFOC
Contact: Donald Collie
Objective: To continue support for the existing contract to complete the ongoing clinical trial evaluating the safety, toxicity, and efficacy of stem cell transplantation for the treatment of scleroderma and the mechanism underlying this intervention.
Description: An ongoing study called: "Randomized Open-label, Phase II Multi-Center Study of High Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation with Auto-CD34+ HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis" (short name: Scleroderma: Cyclophosphamide or Transplantation [SCOT]).